Cours suspendu

Communiqués Merrimack Pharmaceuticals

Actions

MACK

US5903282094

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/05/2024			Varia. 5j.	Varia. 1 janv.
15,13 ^USD	-0,13%		-.--%	-

15/05/24	Merrimack Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
09/05/24	Merrimack Pharmaceuticals, Inc. annonce le montant prévu du dividende final en espèces de la distribution liquidative initiale, payable le 17 mai 2024 ou aux alentours de cette date	CI

Communiqués

13/05/24	Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution and Cash Liquidating Dividend Amount of $15.10 per Share of Common Stock	AQ
10/05/24	Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock	BU
09/05/24	Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution	BU
30/04/24	Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution	BU
27/03/24	Merrimack Receives $225 Million Milestone Payment from Ipsen	BU
07/03/24	Merrimack Reports Full Year 2023 Financial Results	BU
14/02/24	Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma	AQ
13/02/24	Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	BU
02/11/23	Merrimack Reports Third Quarter 2023 Financial Results	BU
03/08/23	Merrimack Reports Second Quarter 2023 Financial Results	BU
04/05/23	MERRIMACK PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
04/05/23	Merrimack Reports First Quarter 2023 Financial Results	BU
04/05/23	MERRIMACK PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
09/03/23	MERRIMACK PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
09/03/23	Merrimack Reports Full Year 2022 Financial Results	BU
09/03/23	MERRIMACK PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
05/12/22	MERRIMACK PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Regulation FD Disclosure (form 8-K)	AQ
05/12/22	Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan	BU
10/11/22	Merrimack Provides Ipsen Report That Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma	AQ
09/11/22	MERRIMACK PHARMACEUTICALS INC : Regulation FD Disclosure, Other Events (form 8-K)	AQ
03/11/22	Merrimack Reports Third Quarter 2022 Financial Results	BU
03/11/22	MERRIMACK PHARMACEUTICALS INC : Regulation FD Disclosure (form 8-K)	AQ
03/11/22	MERRIMACK PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
04/08/22	Merrimack Pharmaceuticals : Reports Second Quarter 2022 Financial Results - Form 8-K	PU
04/08/22	Merrimack Reports Second Quarter 2022 Financial Results	BU